在心力衰竭中,染色体重塑驱动免疫细胞-纤维细胞通信
Michael Alexanian1,2,3, Arun Padmanabhan4,5,6,7, Tomohiro Nishino4,5
1Gladstone Institutes, San Francisco, CA, USA. michael.alexanian@gladstone.ucsf.edu.
Nature
|October 24, 2024
概括
研究人员发现,通过向白蛋白-1β (IL-1β),阻断巨细胞中的Brd4可降低心力衰竭和纤维细胞激活. 这揭示了导致心脏病纤维化的关键炎症途径.
科学领域:
- 免疫学
- 分子生物学
- 心血管研究
背景情况:
- 慢性炎症和组织纤维化会损害器官功能.
- 关联炎症和纤维化的分子机制,特别是纤维细胞激活,尚未完全理解.
- 压力诱导的基因表达变化导致细胞不适应状态和器官功能障碍.
研究的目的:
- 在慢性炎症和心力衰竭的背景下,研究转录协活性剂Brd4的作用.
- 阐明免疫细胞与纤维细胞沟通的分子通路,以驱动纤维细胞的反应.
- 确定潜在的治疗点,以缓解心脏病中的炎症驱动性纤维化.
主要方法:
- 在心力衰竭小鼠模型中,Cx3cr1+巨细胞的条件删除.
- 单细胞染色体可访问性和BRD4占用性分析.
- 基于CRISPR删除控制Il1b表达的调控元素.
- 使用人类心脏纤维细胞的体外研究.
- 在体内以抗体为媒介的IL-1β中和Il1b基因删除.
主要成果:
- 在Cx3cr1+巨细胞中条件删除改善了小鼠的心力衰竭和纤维细胞激活.
- 分泌的IL-1β激活了一种纤维细胞增强剂,导致MEOX1表达和益纤维细胞反应.
- 抗体介导的IL-1β中和Il1b在巨细胞中的缺失改善了心脏功能并减少了纤维化.
- 确定了控制Il1b表达的特定压力依赖的调节元件.
结论:
- 在Cx3cr1+巨细胞中Brd4在促使心肌纤维化的炎症反应中起着至关重要的作用.
- 在激活的巨细胞和纤维细胞之间,IL- 1β起着关键的调解作用,促进纤维状状态.
- 针对免疫细胞中的Brd4-IL-1β-MEOX1轴为心脏病和其他纤维性疾病提供了潜在的治疗策略.
相关概念视频
Pathophysiology of Heart Failure
1.5K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.5K
Chromatin Modification in iPS Cells
1.6K
Chromatin modification alters gene expression; therefore, scientists can add histone-modifying enzymes, histone variants, and chromatin remodeling complexes to somatic cells to aid reprogramming into pluripotent stem (iPS) cells.
Compact chromatin makes reprogramming difficult. Enzymes, such as histone demethylases and acetyltransferases, are often added during reprogramming to loosen the chromatin, making the DNA more accessible to transcription factors. Molecules that inhibit histone...
Compact chromatin makes reprogramming difficult. Enzymes, such as histone demethylases and acetyltransferases, are often added during reprogramming to loosen the chromatin, making the DNA more accessible to transcription factors. Molecules that inhibit histone...
1.6K
Heart Failure II: Pathophysiology
1
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
1
Introduction to Fibroblasts
3.0K
Rudolph Virchow discovered spindle-shaped cells called fibroblasts in 1858. Inactive fibroblasts, called fibrocytes, become activated by various stimuli, such as growth factors and inflammatory cytokines. Activated fibroblasts play a crucial role in wound healing, inflammation, formation of new blood vessels, and cancer progression. Uncontrolled activation of fibroblasts results in fibrosis, the excess deposition of fibrous tissue, which can lead to scarring and affect normal organs. This...
3.0K
Myocarditis I: Introduction
2
Myocarditis is inflammation of the myocardium, which is the muscular layer of the heart.EtiologyMyocarditis has a diverse etiology, including a wide range of infectious and non-infectious causes:Infectious CausesViral: Common viruses include Coxsackie A and B, adenovirus, parvovirus B19, enteroviruses, and influenza A.Bacterial: Examples include infections caused by Streptococcus, Staphylococcus, and Mycoplasma species.Rickettsial: Infections like Rocky Mountain spotted fever can result in...
2
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
394
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
394


